MiRNAs Evaluate the Prognosis of Sepsis (METPS)

This study is currently recruiting participants.
Verified by Chinese PLA General Hospital, September 2010

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Chinese PLA General Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collaborators:</td>
<td>Chinese PLA General Hospital</td>
</tr>
<tr>
<td>Information provided by:</td>
<td>Chinese PLA General Hospital</td>
</tr>
<tr>
<td>ClinicalTrials.gov Identifier:</td>
<td>NCT01207531</td>
</tr>
</tbody>
</table>

Purpose

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis</td>
</tr>
</tbody>
</table>

Study Type: Observational
Study Design: Case-Control, Prospective
Official Title: miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study

Further study details as provided by Chinese PLA General Hospital:

- Biospecimen Retention: Samples Without DNA human serum

- Primary Outcome Measure:
  - all cause mortality  [Time Frame: 28days after admitted in ICU] [Designated as safety issue: No]
Estimated Enrollment: 100
Study Start Date: July 2010
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: November 2010

<table>
<thead>
<tr>
<th>Groups/Cohorts</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival Group</td>
<td></td>
</tr>
<tr>
<td>Death group</td>
<td></td>
</tr>
</tbody>
</table>

The study is a non-intervention, prospective observational study. Purpose of this study is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis. We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009, and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAs expression correlation with SOFA score.

Eligibility

within 24 hours after admitted in ICU

Sampling Method: Non-Probability Sample
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts healthy volunteers.

Inclusion Criteria:

- Clinical diagnosis of sepsis
- Patients who agree with the study

Exclusion Criteria:

- Aged <18 years;
- Into the group who died within 24 hours;
- Agranulocytosis (<0.5 × 109 / L);
- Combined HIV infection.

Contacts and Locations

Contacts
Huijuan Wang, master +86 13466791738 wanghuijuan301@gmail.com

Locations
China, Beijing
Investigators
Study Director: Lixin Xie, Doctor
Pneumology Department of Chinese PLA General Hospital

More Information
Responsible Party: Pneumology Department of Chinese PLA General Hospital (Lixin Xie)
Study ID Numbers: 301PLAGH-2010915
Health Authority: China: Ethics Committee